Dren Bio, Inc., a San Carlos, Calif.-based company developing protein-engineering technologies for depletion of cells, protein aggregates and other disease-causing agents, closed a $60m Series A funding.
The round was led by SR One and Taiho Ventures, LLC , with participation from existing investors 8VC and Mission BioCapital and new investors including BVF Partners L.P., HBM Healthcare Investments, and Alexandria Venture Investments.
Led by Nenad Tomasevic, PhD, Chief Executive Officer and co-founder, Dren is a biotechnology company developing protein engineering technologies to deplete cells, protein aggregates and other disease-causing agents. Its lead programs are initially focused on hematologic neoplasms and solid cancers. Dren is actively working in other areas including auto-immune disorders and diseases of protein aggregation.
The company will use the proceeds to advance its two lead programs through early clinical development. Its first program, DR-01, is an antibody-based therapy to treat rare leukemias and lymphomas as well as specific phenotypes of auto-immune disorders. The second program, DR-02, is an enhanced antibody-based platform to deplete cells and other disease-causing agents through a novel mechanism-of-action.